Skip to main content
Toggle navigation
Login
Search
Home
Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
X
Xia, Huiming
BMS
(
M-121
)
Population Pharmacokinetics and Exposure-Response Analysis Supports Phase 2 Dose Selection for BMS-986288, a non-fucosylated anti-CTLA4 antibody Prodrug
Huiming Xia
Favorite
Xiao, Dan
Merck & Co., Inc.
(
M-122
)
Overcome the Challenges of NONMEM PopPK Dataset for Late Stage Daily Dose Study
Dan Xiao
Favorite
Xu, Christine
Sanofi
(
M-123
)
Streamlining Dupilumab Nasal Polyposis Clinical Development Strategy: Leveraging Modeling and Biomarker Bridging for the Phase 3 Dose Selection
Christine Xu
Favorite
(
M-124
)
Physiologically-based pharmacokinetic modeling approach to support eliglustat development for pediatric patients with Gaucher disease
Christine Xu
Favorite
Xu, Min
The University of Iowa
(
M-125
)
Explore the Impact of Pharmacological Target-Mediated Low Plasma Exposure in Lead Compound Selection in Drug Discovery – a Modeling Approach
Min Xu
Favorite
Xu, Qiushuang (Rachel)
Critical Path Institute
(
T-131
)
A Bayesian Model-based CTS Tool to Optimize Clinical Trial Design in Duchenne Muscular Dystrophy
Qiushuang (Rachel) Xu
Favorite
Xu, Shuang
Certara, Inc.
(
T-132
)
Impacts of dose titration on logistic exposure-response in simulated flexible-dose clinical trials
Shuang Xu
Favorite
Xu, Siyan
Novartis Pharmaceuticals
(
W-134
)
Causal directed acyclic graph (DAG) application in exposure-response analyses
Siyan Xu
Favorite
